Le Lézard
Classified in: Health, Science and technology
Subject: TDS

Delfi Diagnostics to Present at 2022 ASCO Annual Meeting on Multiple Applications for its Next-Generation Liquid Biopsy Platform


BALTIMORE, May 26, 2022 /PRNewswire/ -- Delfi Diagnostics, a pioneering developer of a new class of high-performance, affordable liquid biopsy tests for early cancer detection, will present updates at the 2022 annual meeting of the American Society for Clinical Oncology (ASCO) in Chicago June 3-7 describing multiple applications for its next-generation liquid biopsy platform.

"Delfi has made incredible progress on our screening program over the past year. Additionally, we have identified several new potential applications for our technology that we are continuing to explore," said Victor Velculescu, MD, PhD, Delfi's founder and CEO. "We are excited to share these updates with ASCO's members as we pursue multiple applications on the Delfi platform."

Delfi will present a trial-in-progress update on DELFI-L101, a prospective, case-control study to train and test classifiers for lung cancer detection. Additionally, it will present data showing that Delfi's Tumor Fraction score, DELFI-TFTM, strongly correlates with mutant allele frequency and could serve as a useful tool to monitor tumor burden in patients with advanced cancer.

Presentation details:

Sunday, June 4, 2022, 8 a.m. Central
Cell-free DNA fragmentomes predict tumor burden in metastatic colorectal cancer.
Abstract: 3541 | Poster: 335

About Delfi Diagnostics
Delfi is developing a new class of liquid biopsy tests for early detection based on altered genome-wide fragmentation profiles, also known as "fragmentomes," representing aberrant packaging of DNA in cancer cells. By applying advanced machine learning algorithms, these fragment patterns are detectable at a very low sequencing cost. Delfi is using this technology to develop highly sensitive and specific cancer detection assays intended for wide and cost-effective distribution and adoption.

SOURCE Delfi Diagnostics


These press releases may also interest you

at 08:10
Inspirna, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule cancer therapeutics, announced today data from the ongoing Phase 1b clinical trial studying RGX-202-01 in combination with FOLFIRI and bevacizumab...

at 08:05
NewAmsterdam Pharma (NewAmsterdam), a clinical-stage company focused on the research and development of transformative oral therapies for major metabolic diseases, and the Menarini Group (Menarini), an Italy-based, privately held, international...

at 08:05
Dermavant Sciences, a biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology, today announced that new data from the one-year safety and efficacy final analyses of the Phase 3 PSOARING 3...

at 08:05
PsychoGenics Inc. ("PsychoGenics" or the "Company"), a leader in AI-enabled phenotypic drug discovery and preclinical CRO services, announced today that it has appointed David Bleakman, Ph.D., to President, Drug Discovery and Development, and Thomas...

at 08:05
Wellness Workdays, a leading provider of workplace wellness programs, has been selected by The Haartz Corporation to implement a comprehensive well-being program for Haartz's employees. The program will include Wellness Workdays' robust, easy-to-use...

at 08:05
ProductLife Group (PLG), a global provider of specialized services for the Pharmaceutical, Medtech and Biotech industries, recently acquired Pharma IT, a life sciences consulting company headquartered in Copenhagen, Denmark. Founded in...



News published on 26 may 2022 at 19:06 and distributed by: